PFE Pfizer Inc.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
PFE stock data
()
Calendar
7 Nov 19
7 Dec 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 12.68B | 13.26B | 13.12B | 13.98B | |
| Net income | 7.68B | 5.05B | 3.88B | -393M | |
| Diluted EPS | 1.36 | 0.89 | 0.68 | -0.05 | |
| Net profit margin | 60.57% | 38.04% | 29.61% | -2.81% | |
| Operating income* | 11.13B | 4.52B | 4.68B | -588M | |
| Net change in cash | 1B | -153M | 798M | -2.42B | |
| Cash on hand | 2.79B | 1.78B | 1.94B | 1.14B | |
| Cost of revenue | 2.6B | 2.58B | 2.43B | 3.08B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 53.65B | 52.55B | 52.82B | ||
| Net income | 11.15B | 21.31B | 7.22B | 6.96B | |
| Diluted EPS | 1.87 | 3.52 | 1.17 | 1.11 | |
| Net profit margin | 20.79% | 40.55% | 13.66% | ||
| Operating income* | 13.17B | 13.53B | 9.51B | 10.14B | |
| Net change in cash | -203M | -1.25B | -1.05B | 298M | |
| Cash on hand | 1.14B | 1.34B | 2.6B | 3.64B | |
| Cost of revenue | 11.25B | 11.23B | 12.32B | 9.65B |
Financial data from Pfizer earnings reports. *Asterisk values are approximate.
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
abandoned, abrocitinib, adjudicated, adjudication, akcea, amlodipine, antisense, attachment, BEACON, bidder, binimetinib, Braftovi, broad, cap, CDI, Chapel, checkpoint, CHMP, clearance, College, confidential, conveyed, copay, copy, creativity, Creek, database, demerger, derecognized, encorafenib, Fabre, FCPA, Glenmark, globulin, heart, Hill, hip, HIPAA, immunosuppression, incidence, infection, Inquiry, introduction, JV, Kit, knee, Likewise, LLP, locked, lymphoproliferative, Mektovi, metabolic, Missouri, NaN, Neulasta, nonsteroidal, OA, Octagam, Panzyga, pegfilgrastim, percent, pharmacovigilance, Pierre, polyneuropathy, PRAC, principle, procedure, qualification, Relpax, Rodino, Russian, Sanford, SC, slightly, superseded, tied, tumor, unamortized, uncertainty, unvested, urgency, Utah, VBP, viii
Financial reports
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
22 Feb 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
10 Aug 17
Current reports
8-K
Pfizer Reports Third-quarter 2019 Results
29 Oct 19
8-K
Departure of Directors or Certain Officers
27 Sep 19
8-K
Pfizer Announces Closing of Joint Venture with Glaxosmithkline to Create a Premier Global Consumer Healthcare Company
5 Aug 19
8-K
Pfizer Reports Second-quarter 2019 Results
29 Jul 19
8-K
Entry into a Material Definitive Agreement
29 Jul 19
8-K
Scott Gottlieb Elected to Pfizer’s Board of Directors
27 Jun 19
8-K
Regulation FD Disclosure
17 Jun 19
8-K
Pfizer Reports First-quarter 2019 Results
30 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
29 Apr 19
8-K
Other Events
11 Mar 19
Registration and prospectus
425
Business combination disclosure
12 Nov 19
425
Business combination disclosure
31 Oct 19
425
Business combination disclosure
10 Sep 19
425
Business combination disclosure
4 Sep 19
425
Business combination disclosure
30 Aug 19
S-8
Registration of securities for employees
9 Aug 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 19
425
Business combination disclosure
2 Aug 19
425
Business combination disclosure
1 Aug 19
425
Business combination disclosure
31 Jul 19
Proxies
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
PX14A6G
Letter to shareholders
18 Apr 18
DEFA14A
Additional proxy soliciting materials
6 Apr 18
PX14A6G
Letter to shareholders
6 Apr 18
DEF 14A
Definitive proxy
15 Mar 18
DEFA14A
Additional proxy soliciting materials
15 Mar 18
Other
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17
NO ACT
No action letter
26 Jan 17
NO ACT
No action letter
10 Jan 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
SC 13G
Cortexyme, Inc.
22 May 19
SC 13G
NextCure, Inc.
22 May 19
SC 13G
Pfizer Inc
14 Feb 19
SC 13G/A
Rhythm Pharmaceuticals, Inc.
13 Feb 19
SC 13G/A
Gemphire Therapeutics Inc.
13 Feb 19
SC 13G/A
Pfizer Inc
11 Feb 19
SC 13G/A
Pfizer Inc
6 Feb 19
SC 13D/A
Icu Medical Inc/de
16 Nov 18
SC 13D
Allogene Therapeutics, Inc.
22 Oct 18
SC 13D/A
Icu Medical Inc/de
15 Aug 18
Patents
APP
Utility
Crystalline Form of Lorlatinib Free Base
5 Dec 19
This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7).
APP
Utility
Purification of Antibody Drug Conjugates Using a Sodium Phosphate Gradient
5 Dec 19
Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
APP
Utility
Heteroaromatic Compounds and Their Use As Dopamine D1 Ligands
5 Dec 19
Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
GRANT
Design
Therapeutic wrap
3 Dec 19
Inventors: Clayton Jay Bigelow, Mark Edward Fagan, Chad Kamil Hickson, Amy Michelle Martini
GRANT
Design
Therapeutic wrap
3 Dec 19
Inventors: Clayton Jay Bigelow, Mark Edward Fagan, Chad Kamil Hickson, Amy Michelle Martini